ClinicalTrials.gg
CompletedNCT01078662Updated Aug 13, 2025Results posted

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

A Phase 2 interventional study of olaparib in Ovarian, Breast and Prostate, sponsored by AstraZeneca. Completed at 14 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-08-13.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
298
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

To assess the efficacy of oral olaparib in patients with advanced cancer who have a confirmed genetic BRCA1 and/or BRCA2 mutation, by assessment of tumour response

02

Conditions studied

  • Ovarian
  • Breast
  • Prostate
  • Pancreatic
  • Advanced Tumours

Keywords

  • olaparib
  • PARP inhibitors
  • genetic BRCA1 mutation
  • BRCA2 mutation
  • solid tumour refractory
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed documented deleterious or suspected deleterious BRCA mutation. (The presence of a loss-of-function germline mutation in the BRCA1 and/or BRCA2 gene must be confirmed prior to consent according to local practice).
  • Confirmed malignant solid tumours for which no standard treatment exists
  • At least one lesion (measurable and/or non measurable) at baseline that can be accurately assessed by CT/MRI and is suitable for repeated assessment at follow up visits

Exclusion criteria

Exclusion Criteria:

  • Any previous treatment with a PARP inhibitor, including olaparib
  • Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication
  • Patients receiving any systematic chemotherapy, radiotherapy (except for palliative reasons) within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used)
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
298 participants (actual)

Study arms

  • Experimental
    1

    Olaparib is available as a film-coated tablet containing 150 mg or 100 mg of olaparib. Subjects will be administered study treatment orally at a dose recommended by Investigator. Full dose: 300 mg twice daily (bid) or Reduced doses: 200 mg twice daily (bid) or 100 mg twice daily (bid). The planned dose of 300 mg bid will be made up of two x 150 mg tablets twice daily, with 100 mg tablets used to manage dose reductions.

    Drug: olaparib

Interventions

  • Tablets Oral BID

    Also known as: Lynparza

06

What researchers measure

Primary outcomes

  1. Tumour Response Rate

    Tumour response rate is the proportion of patients who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).

    Time frame: Tumour assessments carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months

Secondary outcomes

  1. Objective Response Rate

    Objective response rate is the proportion of patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).

    Time frame: Tumour assessments carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months

  2. Progression Free Survival

    Progression free survival is defined as the duration from first dose till objective progression or death. In absence of progression or death, the time is calculated from first dose till last evaluable scanning visit.

    Time frame: Tumour assessments are carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months

  3. Overall Survival

    Overall survival is defined as the duration from first dose till death. In absence of death, the time is calculated from first dose till the date subject last known to be alive.

    Time frame: Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed maximum up to 29 months

  4. Overall Survival Rate at 12 Months

    Overall survival rate at 12 months is defined as the proportion of patients who are alive 12 months after date of first dose

    Time frame: Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed maximum up to 29 months

  5. Duration of Response

    Duration of response is calculated from the date of first documented response (complete or partial) until date of documented progression (as defined by RECIST 1.1) or death (by any cause) in the absence of disease progression.

    Time frame: From onset of first occurrence of complete or partial response till documented progression or death by any cause in the absence of progression, assessed maximum up to 29 months

  6. Disease Control Rate at Week 16

    Disease control rate is the proportion of patients with best response of complete or partial response or stable disease according to definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) till week 16.

    Time frame: Tumour assessments carried out at baseline ie 28 days before first study drug dose and then at week 8 and week 16

07

Results

Posted May 22, 2015

Participant flow

This study was conducted at 13 sites across Israel, Germany, Spain, Australia, USA, Sweden. Enrolment started in Feb 2010 and was completed in Jul 2012. In total, 298 patients had received treatment (olaparib).

Participant flow — Overall Study
MilestoneBreast CancerOvarian CancerPancreatic CancerProstate CancerOther Cancers
Started6219323812
Completed425211
Not completed5816821711
Withdrew: Death411031858
Withdrew: Patients reached data cut-off1253223
Withdrew: Withdrawal by subject411100
Withdrew: Protocol violation01000
Withdrew: Lost to follow-up10000

Outcome measures

PrimaryTumour Response Rate

Tumour response rate is the proportion of patients who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).

Time frame:
Tumour assessments carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months
Reported as:
Number · Percentage of participants
Tumour Response Rate
Percentage of participantsBreast CancerOvarian CancerPancreatic CancerProstate CancerOther CancersAll Patients
Tumour Response Rate12.9 (5.74 to 23.85)31.1 (24.64 to 38.13)21.7 (7.46 to 43.7)50 (15.7 to 84.3)8.3 (0.21 to 38.48)26.2 (21.27 to 31.55)
SecondaryObjective Response Rate

Objective response rate is the proportion of patients with at least one measurable lesion at baseline, who experienced complete or partial response at least once during the assessment period, according to the definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1).

Time frame:
Tumour assessments carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months
Reported as:
Number · Percentage of participants
Objective Response Rate
Percentage of participantsBreast CancerOvarian CancerPancreatic CancerProstate CancerOther CancersAll Patients
Objective Response Rate13.8 (6.15 to 25.38)35.9 (28.66 to 43.7)21.7 (7.46 to 43.7)57.1 (18.41 to 90.1)9.1 (0.23 to 41.28)29.3 (23.92 to 35.19)
SecondaryProgression Free Survival

Progression free survival is defined as the duration from first dose till objective progression or death. In absence of progression or death, the time is calculated from first dose till last evaluable scanning visit.

Time frame:
Tumour assessments are carried out at baseline ie 28 days before first study drug dose and then every 8 weeks up to 6 months after starting study treatment, then every 12 weeks until objective disease progression, assessed maximum up to 29 months
Reported as:
Median · months
Progression Free Survival
monthsBreast CancerOvarian CancerPancreatic CancerProstate Cancer
Progression Free Survival3.68 (1.76 to 7.52)7.03 (3.65 to 11.24)4.55 (1.81 to 8.21)7.15 (2.63 to 17.45)
SecondaryOverall Survival

Overall survival is defined as the duration from first dose till death. In absence of death, the time is calculated from first dose till the date subject last known to be alive.

Time frame:
Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed maximum up to 29 months
Reported as:
Median · months
Overall Survival
monthsBreast CancerOvarian CancerPancreatic CancerProstate Cancer
Overall Survival11.01 (5.68 to 24.18)16.62 (9.43 to NA)9.81 (3.84 to 16.62)18.38 (6.24 to 25.46)
SecondaryOverall Survival Rate at 12 Months

Overall survival rate at 12 months is defined as the proportion of patients who are alive 12 months after date of first dose

Time frame:
Survival follow-up from first dose till death of the patient or till end of study in absence of death, assessed maximum up to 29 months
Reported as:
Number · Percentage of participants
Overall Survival Rate at 12 Months
Percentage of participantsBreast CancerOvarian CancerPancreatic CancerProstate Cancer
Overall Survival Rate at 12 Months44.7 (5.68 to 24.18)64.4 (9.43 to NA)40.9 (3.84 to 16.62)50 (6.24 to 25.46)
SecondaryDuration of Response

Duration of response is calculated from the date of first documented response (complete or partial) until date of documented progression (as defined by RECIST 1.1) or death (by any cause) in the absence of disease progression.

Time frame:
From onset of first occurrence of complete or partial response till documented progression or death by any cause in the absence of progression, assessed maximum up to 29 months
Reported as:
Median · days
Duration of Response
daysBreast CancerOvarian CancerPancreatic CancerProstate CancerOther CancersAll Patients
Duration of Response204 (149.5 to 405)225 (143 to 410)134 (131 to 141)326.5 (164 to 476)165 (165 to 165)208 (134 to 410)
SecondaryDisease Control Rate at Week 16

Disease control rate is the proportion of patients with best response of complete or partial response or stable disease according to definitions of Response Evaluation Criteria In Solid Tumours (RECIST version 1.1) till week 16.

Time frame:
Tumour assessments carried out at baseline ie 28 days before first study drug dose and then at week 8 and week 16
Reported as:
Number · Percentage of participants
Disease Control Rate at Week 16
Percentage of participantsBreast CancerOvarian CancerPancreatic CancerProstate CancerOther CancersAll Patients
Disease Control Rate at Week 1637.1 (25.16 to 50.31)58 (50.73 to 65.08)47.8 (26.82 to 69.41)62.5 (24.49 to 91.48)33.3 (9.92 to 65.11)52 (46.18 to 57.81)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OLAPARIB—90/298 (30.2%)290/298 (97.3%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventOLAPARIB
ANAEMIABlood and lymphatic system disorders13/298
ABDOMINAL PAINGastrointestinal disorders11/298
INTESTINAL OBSTRUCTIONGastrointestinal disorders7/298
SMALL INTESTINAL OBSTRUCTIONGastrointestinal disorders7/298
VOMITINGGastrointestinal disorders5/298
PNEUMONIAInfections and infestations4/298
DYSPNOEARespiratory, thoracic and mediastinal disorders4/298
PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders4/298
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders4/298
THROMBOCYTOPENIABlood and lymphatic system disorders3/298
Most frequent other events
Showing 10 of 41
Most frequent other events
EventOLAPARIB
NAUSEAGastrointestinal disorders176/298
FATIGUEGeneral disorders176/298
VOMITINGGastrointestinal disorders109/298
ANAEMIABlood and lymphatic system disorders90/298
DIARRHOEAGastrointestinal disorders81/298
ABDOMINAL PAINGastrointestinal disorders66/298
DECREASED APPETITEMetabolism and nutrition disorders62/298
DYSPEPSIAGastrointestinal disorders52/298
HEADACHENervous system disorders48/298
DYSGEUSIANervous system disorders47/298

Baseline characteristics

Age, Continuous
Age, Continuous(years)Breast CancerOvarian CancerPancreatic CancerProstate CancerOther CancersTotal
Mean47.6 ± 9.6957.2 ± 9.2857.1 ± 7.9966.6 ± 9.8654.9 ± 12.3855.3 ± 10.3
Age, Customized
Age, Customized(Participants)Breast CancerOvarian CancerPancreatic CancerProstate CancerOther CancersTotal
< 50 years334060483
>=50 to <65 years281171435167
>= 65 years13635348
Sex: Female, Male
Sex: Female, Male(Participants)Breast CancerOvarian CancerPancreatic CancerProstate CancerOther CancersTotal
Female611931008272
Male10138426
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Breast CancerOvarian CancerPancreatic CancerProstate CancerOther CancersTotal
White6018321811283
Black or African American011002
Asian1810111
Other110002
08

Study locations

14 sites
  • Research Site
    West Hollywood, California 90048, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Randwick, 2031, Australia
  • Research Site
    Cologne, 50931, Germany
  • Research Site
    Haifa, 31096, Israel
  • Research Site
    Haifa, 35152, Israel
  • Research Site
    Jerusalem, 91031, Israel
  • Research Site
    Jerusalem, 91120, Israel
  • Research Site
    Petah Tikva, 49100, Israel
  • Research Site
    Ramat Gan, 52621, Israel
  • Research Site
    Tel Aviv, Israel
  • Research Site
    Madrid, 08035, Spain
  • Research Site
    Lund, 221 85, Sweden
09

References and documents

Publications

  • Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW, Kaye S, Molife LR, Gelmon KA, Robertson JD, Mann H, Ho TW, Coleman RL. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016 Jun;27(6):1013-1019. doi: 10.1093/annonc/mdw133. Epub 2016 Mar 8. PubMed 26961146 ↗
  • Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Loman N, Robertson JD, Mann H, Kaufman B. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016 Feb;140(2):199-203. doi: 10.1016/j.ygyno.2015.12.020. Epub 2015 Dec 23. PubMed 26723501 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2010 to primary completion in Jul 2012, 29 months.

Results were first posted in May 2015, 2 years 9 months after primary completion. A results delay was requested in May 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2010
First posted
Mar 2, 2010
StartActual
Feb 21, 2010
Primary completionActual
Jul 31, 2012
CompletionActual
Aug 12, 2024
Results delay requested
May 9, 2013
Results first posted
May 22, 2015
Last update
Aug 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01078662
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Mar 2, 2010
Start date
Feb 21, 2010
Primary completion
Jul 31, 2012
Completion
Aug 12, 2024
Results posted
May 22, 2015
Last update
Aug 13, 2025

Study contacts

Jane Robertson, BSc, MBCHB, MD
study director · AstraZeneca
Bella Kaufman, MD
principal investigator · Chaim Sheba Medical Centre, Tel Hashomer, Israel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olaparib

Start the discussion